Evidence map›Paper›PMID 28061949›Full record

ArticleTuberculosis (Edinburgh, Scotland)2017

Mycobacterium tuberculosis Rv0560c is not essential for growth in vitro or in macrophages.

Rachel Kokoczka, Dorothée L Schuessler, Julie V Early, Tanya Parish

Open access · greenAbstract read
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. The Inhibitory Effect of GlmU Acetyltransferase Inhibitor TPSA onFrontiers in cellular and infection microbiology · 2019
    Article
  4. Methionine AntagonizesFrontiers in cellular and infection microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Rachel KokoczkaTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, United States.
Dorothée L SchuesslerQueen Mary University of London, Barts and the London School of Medicine and Dentistry, London, E1 2AD, UK.
Julie V EarlyTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, United States.
Tanya ParishTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, United States; Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, E1 2AD, UK. Electronic address: tanya.parish@idri.org.
Infectious Disease Research Institute · USQueen Mary University of London · GB

Funding

Sterol/Hopanoid Biosynthesis: An Anti-TB Drug TargetR01AI049151 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI CRICK, DEAN C · 2001 to 2019
$4.1M
NIAID NIH HHS R01 AI049151
6 · The paper itself

Abstract

Mycobacterium tuberculosis Rv0560c, a putative benzoquinone methyl transferase, is heavily induced in response to salicylate exposure. It has some similarity to Escherichia coli UbiG, although its role in ubiquinone or menaquinone synthesis is not clear, since M. tuberculosis is not known to produce ubiquinone. We constructed an unmarked in-frame deletion of Rv0560c in M. tuberculosis to determine its role in vitro. Deletion of Rv0560c in M. tuberculosis had no effect on growth in medium containing salicylate or in its ability to grow in macrophages. In addition, no change to compound sensitivity, as determined by minimum inhibitory concentrations, for a range of compounds targeting respiration was noted. Plumbagin, ethambutol and CCCP had the same minimum bactericidal concentration against the deletion and wild-type strains. Taken together these data show that Rv0560c is dispensable under in vitro conditions in both axenic and macrophage culture and suggest that the role of Rv0560c may be in an alternate biosynthetic pathway of menaquinone which is only used under specific growth conditions.

Indexed as

Antibiotics, AntitubercularCell DivisionCells, CulturedCulture MediaGene DeletionGenes, BacterialHumansMacrophagesMicrobial Sensitivity TestsMycobacterium tuberculosisSalicylatesAntibiotics, AntitubercularCulture MediaSalicylatesMenaquinoneMycobacteriaNon-essential genesVirulence

Identifiers

PMID28061949
PMCPMC5225668
OpenAlexW2546704793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.